EnGeneIC
Latest round
- Series B
Last raised
- Jan 2015
Total raised
- $11M
Investors
- 2
About EnGeneIC
EnGeneIC Ltd.Founded in 2000 and headquartered in Sydney, Australia, EnGeneIC Ltd. specializes in targeted cancer therapies. The company has undergone strategic pivots towards developing its proprietary EDV™ technology for treating cancers expressing the Epidermal Growth Factor Receptor (EGFR).EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, focusing on its proprietary EnGeneIC Dream Vector (EDV™) technology. Their core offerings include EGFR-targeted EDV™ nanocells that deliver the super-cytotoxic drug PNU-159682 and EDVs containing immune-stimulating adjuvants. These therapies target patients with advanced solid tumors expressing EGFR, fulfilling critical needs in cancer treatment. Initial clinical evaluations, including a multicenter Phase I/IIa trial at Mater Hospital in Sydney, have been conducted to establish safety and efficacy.30. The company's revenue model is based on strategic partnerships and advancing clinical trials, creating revenue streams through technology transfer and GMP batch manufacturing of EDV™ nanocells. The focus is on expanding into new markets, particularly in Asia, by establishing strategic partnerships aimed at enhancing distribution capabilities. Upcoming product launches are expected to align with clinical trial advancements, although specific release dates have not been disclosed.
Who invested in EnGeneIC
2 investors across 1 round
See all investors in EnGeneIC
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jan 6, 2015
Amount
$11M
Investors
Questions about EnGeneIC
Who invested in EnGeneIC?
EnGeneIC has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EnGeneIC raised?
EnGeneIC has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did EnGeneIC last raise money?
EnGeneIC's most recent round on record is a Series B, in Jan 2015.
What does EnGeneIC do?
EnGeneIC is a biotechnology company.
Where is EnGeneIC headquartered?
EnGeneIC is headquartered in Sydney, Australia.
Which VCs invest in companies like EnGeneIC?
Among active investors with capital left to deploy, Blackbird, AirTree Ventures, Square Peg and Movac back biotechnology companies at EnGeneIC's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like EnGeneIC? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.